



7th GUILDFORD ADVANCED PAIN & SYMPTOM MANAGEMENT COURSES

REFERENCE / READING LIST

ALTERNATIVE ROUTES OF ADMINISTRATION

Andrew Dickman

- Dickman A, Bickerstaff M, Jackson R, Schneider J, Mason S, Ellershaw J. Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability. *BMC Palliat Care*. 2017 Mar 23;16(1):22. [Copy of paper available on course website].
- Newton DW. Drug incompatibility chemistry. *Am J Health Syst Pharm*. 2009 Feb 15;66(4):348-57.

UPDATE ON TRANSDERMAL FENTANYL

David Brooks

- Marija Bakovic, Marina Nestic, Davor Mayer. 2015. Death by band-aid: fatal misuse of transdermal fentanyl patch. *International Journal of Legal Medicine* 129:1247-1252
- Martin Juebner, Mathias Fietzke, Justus Beike, Markus A. Rothschild, Katjia Bender. 2014. Assisted Suicide by fentanyl intoxication due to excessive transdermal application. *International Journal of Legal Medicine* 128:949-956
- Adam Joseph Trist, Hardeep Sahota, Lucy Williams. 2017. Not so patchy story of attempted suicide...leading to 24 hours of deep sleep and survival! *BMJ Case Reports* 1644:126-25
- Kazhuliko Koike, Takeshi Terui, Tomokazu Nagasako, Iori Horiuchi, Takayuki Machino, Toshiro Kusakabe, Yasuo Hirayama, Hiroyoshi Mihara, Michiaki Yamakage, Junji Kato, Takuji Nishisato, Kunihiko Ishitani. 2016. A new once-a-day fentanyl citrate patch could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch. *Support Care Cancer* 24:1053-1059

- Lesley J. Scott. 2016. Fentanyl Iontophoretic Transdermal System: A Review in Acute Postoperative Pain. *Clin Drug Investigation* 36:321-330
- Astrid W. Oosten, Joao A. Abrantes, Siv Jonsson, Peter de Bruijn, Evelien J.M. Kuip, Amilcar Falcao, Cairn C.D. van de Rijt, Ron H.J. Mathijssen. 2016. Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. *European Journal of Clinical Pharmacology* 72:459-467
- Daniel T. Barratt, Pai Klepstad, Ola Dale, Stein Kaasa, Andrew A. Somogyi. 2015. Innate immune signalling genetics of pain, cognitive dysfunction and sickness symptoms in cancer pain patients treated with transdermal fentanyl. *PLoS ONE* 10:e0137179
- Sudeep Raj Bista, Janet Hardy, Angela Tapuni, Jinlin Fu, Kirsten Gibbons, et al. 2015. Validation of a fentanyl transdermal adhesion scoring tool for use in clinical practice. *Journal of Pain and Symptom Management* 49:934-938
- Shao-Zhi Xing, Ying Zhang. 2015. Efficacy and safety of transdermal fentanyl for the treatment of oral mucositis pain caused by chemoradiotherapy in patients with esophageal squamous cell carcinoma. *Supportive Care in Cancer* 23:753-759
- Akhila Reddy, Sriram Yennurajalingam, Suresh Reddy, Jimin Wu, Diane Liu, Rony Dev, Eduardo Bruera. 2016. The opioid rotation ratio from transdermal fentanyl to “strong” opioids in patients with cancer pain. *Journal of Pain and Symptom Management* 51:1040-1045
- Nurdan Unlu, Aysegul Bilen, Achmet Ali, Namigar Turgut, Aygen Turkmen, et Al. 2014. The cognitive effects of using transdermal fentanyl in cancer pain. *The Journal of the Turkish Society of Algology* 26:126-130
- S Derry, C Cole, PJ Wiffen, R Knaggs, D Aldington, R Moore. 2016. Fentanyl for neuropathic pain in adults. *Cochrane Database of Systematic Reviews*.
- G Hadley, S Derry, R Moore, PJ Wiffen. 2013. Fentanyl for neuropathic pain in adults. *Cochrane Database of Systematic Reviews*.
- Philip J Wiffen, Bee Wee, Sheena Derry, Rae F Bell, R Andrew Moore. 2017. Opioids for cancer pain – an overview of Cochrane reviews. *Cochrane Database of Systematic Reviews*.
- Philip J Wiffen, Sheena Derry, R Andrew Moore. 2014. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. *Cochrane Database of Systematic Reviews*.

- Dong-Dong Wang, Ting-Ting Ma, Hua-Dong Zhu, Cong-Bin Peng. 2018. Transdermal fentanyl for cancer pain: trial sequential analysis of 3406 patients from 35 randomized controlled trials. *Journal of Cancer Research and Therapeutics* 14:14-21
- Leena Choi, Benjamin A Ferrell, Eduard E Vasilevskis, Pratik P Pandharipande, Rebecca Heltsley, E Wesley Ely, C Michael Stein, Timothy D Girard. 2016. Population pharmacokinetics of fentanyl in the critically ill. *Critical Care Medicine* 44:64-72

OPIOID ADVERSE EFFECTS - NOT THE “USUAL SUSPECTS”!

Andrew Davies

- Vervloet D, Durham S. Adverse reactions to drugs. *British Medical Journal* 1998; 316: 1511-4.
- Oosten AW, Oldenmenger WH, Mathijssen RH et al. A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. *Journal of Pain* 2015; 16: 935-946. [Copy of paper available on course website].
- Potter J, Hami F, Bryan T, Quigley C. Symptoms in 400 patients referred to palliative care services: prevalence and patterns. *Palliative Medicine* 2003; 17: 310-4.
- Shorthose K, Davies A. Symptom prevalence in palliative care. *Palliative Medicine* 2003; 17: 723-4.
- Fountain A. Visual hallucinations: a prevalence study among hospice inpatients. *Palliative Medicine* 2001; 15: 19-25.
- Davies AN, Quinn T. Opioid-related musical hallucinations. *Journal of Pain and Symptom Management* 2005; 29: 327-8. [Copy of paper will be available on course website].
- Davies AN, Patel SD, Gregory A, Lee B. Observational study of sleep disturbance in advanced cancer. *BMJ Supportive and Palliative Care* 2017; 7: 435-40. [Copy of paper will be available on course website].
- Cheatle MD, Webster LR. Opioid therapy and sleep disorders: risks and mitigation strategies. *Pain Medicine* 2015; 16; S22-6. [Copy of paper available on course website].

ACUPUNCTURE FOR PAIN RELIEF

Graham Leng

- Wu X, Chung VC, Hui EP, Ziea ET, Ng BF, Ho RS, Tsoi KK, Wong SY, Wu JC. Effectiveness of acupuncture and related therapies for palliative care of cancer:

- overview of systematic reviews. *Sci Rep.* 2015 Nov 26;5:16776 [Copy of paper available on course website].
- Leng G. Use of acupuncture in hospices and palliative care services in the UK. *Acupunct Med.* 2013 Mar;31(1):16-22 [Copy of paper available on course website].
 - Standish LJ, Kozak L, Congdon S. Acupuncture is underutilized in hospice and palliative medicine. *Am J Hosp Palliat Care.* 2008 Aug-Sep;25(4):298-308
 - White A. The safety of acupuncture – evidence from the UK. *Acupunct Med* 2006; 24(Suppl):S53-57

 - Chiu HY, Hsieh YJ, Tsai PS. Systematic review and meta-analysis of acupuncture to reduce cancer-related pain. *Eur J Cancer Care (Engl).* 2017 Mar;26(2)
 - Chen L, Lin CC, Huang TW, Kuan YC, Huang YH, Chen HC, Kao CY, Su CM, Tam KW. Effect of acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer: A meta-analysis of randomized controlled trials. *Breast.* 2017 Jun;33:132-138
 - Hu C, Zhang H, Wu W, Yu W, Li Y, Bai J, Luo B, Li S. Acupuncture for Pain Management in Cancer: A Systematic Review and Meta-Analysis. *Evidence-Based Complementary and Alternative Medicine Volume 2016, Article ID 1720239* [Copy of paper available on course website].
 - Vickers AJ, Vertosick EA, Lewith G, MacPherson H, Foster NE, Sherman KJ, Irnich D, Witt CM, Linde K; Acupuncture Trialists' Collaboration. Acupuncture for Chronic Pain: Update of an Individual Patient Data Meta-Analysis. *J Pain.* 2018 May;19(5):455-474
 - Franconi G, Manni L, Schröder S, Marchetti P, Robinson N. A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy. *Evid Based Complement Alternat Med.* 2013;2013:516916

 - Lee A, Chan SK, Fan LT. Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting. *Cochrane Database Syst Rev.* 2015 Nov 2;(11):CD003281
 - Ezzo J, Vickers A, Richardson MA, Allen C, Dibble SL, Issell B, Lao L, Pearl M, Ramirez G, Roscoe JA, Shen J, Shivnan J, Streitberger K, Treish I, Zhang G. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. *J Clin Oncol.* 2005 Oct 1;23(28):7188-98

- Vickers AJ. Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. *J R Soc Med.* 1996 Jun;89(6):303-11
- Coyle ME, Shergis JL, Huang ET, Guo X, Di YM, Zhang A, Xue CC. Acupuncture therapies for chronic obstructive pulmonary disease: a systematic review of randomized, controlled trials. *Altern Ther Health Med.* 2014 Nov-Dec;20(6):10-23
- Simcock R, Fallowfield L, Monson K, Solis-Trapala I, Parlour L, Langridge C, Jenkins V; ARIX Steering Committee. ARIX: a randomised trial of acupuncture v oral care sessions in patients with chronic xerostomia following treatment of head and neck cancer. *Ann Oncol.* 2013 Mar;24(3):776-83
- Tao WW, Tao XM, Song CL. Effects of non-pharmacological supportive care for hot flushes in breast cancer: a meta-analysis. *Support Care Cancer.* 2017 Jul;25(7):2335-2347
- Chien TJ, Hsu CH, Liu CY, Fang CJ. Effect of acupuncture on hot flush and menopause symptoms in breast cancer- A systematic review and meta-analysis. *PLoS One.* 2017 Aug 22;12(8)
- Chen YP, Liu T, Peng YY, Wang YP, Chen H, Fan YF, Zhang L. Acupuncture for hot flashes in women with breast cancer: A systematic review. *J Cancer Res Ther.* 2016 Apr-Jun;12(2):535-42
- Forde JC, Jaffe E, Stone BV, Te AE, Espinosa G, Chughtai B. The role of acupuncture in managing overactive bladder; a review of the literature. *Int Urogynecol J.* 2016 Nov;27(11):1645-1651
- Zhang Y, Lin L, Li H, Hu Y, Tian L. Effects of acupuncture on cancer-related fatigue: a meta-analysis. *Support Care Cancer.* 2018 Feb;26(2):415-425
- Filshie J, Hester J. Guidelines for providing acupuncture treatment for cancer patients – a peer-reviewed sample policy document. *Acupunct Med* 2006;24(4):172-182
- Filshie J. Safety Aspects of Acupuncture in Palliative Care. *Acupunct Med* 2001;19(2):117-122
- National Guidelines for the Use of Complementary Therapies in Supportive and Palliative Care. Tavares M. The Prince of Wales's Foundation for Integrated Health and the National Council for Hospice and Specialist Palliative Care Services, 2003
- British Medical Acupuncture Society
www.medical-acupuncture.co.uk
- Acupuncture in Medicine journal

<https://aim.bmj.com>

- BMAS training in acupuncture
www.medical-acupuncture.co.uk/TrainingEducation/Acupuncturetraining.aspx

WHAT ELSE IS NEW (PAIN)?

Andrew Davies

- Smith HS. Potential analgesic mechanisms of acetaminophen. *Pain Physician* 2009; 12: 269-80. [Copy of paper available on course website].
- Wiffen PJ, Derry S, Moore RA et al. Oral paracetamol (acetaminophen) for cancer pain. *Cochrane Database of Systematic Reviews* 2017, Issue 7. Art. No.: CD012637. [Copy of paper available on course website].
- Davies AN, Vriens J, Webber K et al. An observational study of paracetamol (acetaminophen) deprescribing in patients with cancer pain receiving opioids for moderate-to-severe pain. *Medycyna Paliatywna w Praktyce* 2017; 11: 133-7. [Copy of paper available on course website].
- Axelsson B, Stellborn P, Strom G. Analgesic effect of paracetamol on cancer related pain in concurrent strong opioid therapy. A prospective clinical study. *Acta Oncologica* 2008; 47: 891-5.
- Jibril F, Sharaby S, Mohamed A et al. Intravenous versus oral acetaminophen for pain: systematic review of current evidence to support clinical decision-making. *Canadian Journal of Hospital Pharmacy* 2015; 68: 238-47.
- Raffa RB, Pawasauskas J, Pergolizzi JV et al. Pharmacokinetics of oral and intravenous paracetamol (acetaminophen) when co-administered with intravenous morphine in healthy adult subjects. *Clinical Drug Investigation* 2018; 38: 259-68.
- Carr AC, McCall C. The role of vitamin C in the treatment of pain: new insights. *Journal of Translational Medicine* 2017; 15: 77.
- Helde-Frankling M, Bjorkhem-Bergman L. Vitamin D in pain management. *International Journal of Molecular Sciences*. [Copy of paper available on course website].
- Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health. *American Journal of Clinical Nutrition* 2008; 87(Suppl): 1080S-6S. [Copy of paper available on course website].
- Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem. *Journal of Steroid Biochemistry and Molecular Biology* 2014; 144 Part A: 139-45.

- Bergman P, Sperner S, Holjer J et al. Low vitamin D levels are associated with higher opioid dose in palliative cancer patients - results from an observational study in Sweden. *Plos One* 2015; 10: e0128223.
- Helde-Frankling M, Holjer J, Begqvist L et al. Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections - results from a matched case-control study. *Plos One* 2017; 12: e0184208. [Copy of paper available on course website].

PAIN - WHAT IT DOES TO US, AND WHAT CAN WE DO ABOUT IT?

Tony Dickenson

- Bannister K, Kucharczyk M, Dickenson AH. Hopes for the future of pain. *Pain Ther* 2017; 6: 117-28. [Copy of paper available on course website].
- Colloca L, Ludman T, Bouhassira D et al. Neuropathic pain. *Nat Rev Dis Primers* 2017; 3: 17002. [Copy of paper available on course website].
- Falk S, Dickenson AH. Pain and nociception: mechanisms of cancer-induced bone pain. *J Clin Oncol* 2014; 32: 1647-54.

SYMPTOM ASSESSMENT

Jo Thompson

- Ahmed N, Ahmedzai S, Collins K et al. Holistic assessment of supportive and palliative care needs: the evidence for routine, systematic questioning. *BMJ Supportive and Palliative Care* 2014; 0: 1-9
- Aslakson R, Dy S, Wilson R et al. Patient and caregiver-reported assessment tools for palliative care: Summary of the 2017 agency for healthcare research and quality technical brief. *Journal of Pain and Symptom Management* 2017; 4: 961-973.
- Barresi M, Shadbolt B, Byrne D et al. The development of the Canberra symptom scorecard: a tool to monitor the physical symptoms of patients with advanced tumours. *BMC Cancer* 2003; 3: 1-9.
- Browner I, Smith T. Symptom assessment in elderly cancer patients receiving palliative care. *Annals of Oncology* 2013; 23:125-129.
- Chang V, Hwang S, Kasimis B et al. Shorter symptom assessment instruments: the Condensed Memorial Symptom Assessment Scale (CMSAS). *Cancer Investigation* 2004; 22: 526-536.

- Chang V, Hwang S, Feuerman M et al. Validation of the Edmonton symptom assessment scale. *Cancer* 2000; 88: 2164-2171.
- Chang V, Hwang S, Feuerman M et al. The Memorial Symptom Assessment Scale Short Form (MSAS-SF). *Cancer* 2000; 89: 1162-1171
- Clement S, Woodgate R, Degner L. Symptom distress in adult patients with cancer. *Cancer Nursing* 1997; 20: 236-243
- Ewing G, Rogers M, Barclay S et al. Palliative care in primary care: a study to determine whether patients and professionals agree on symptoms. *British Journal of General Practice* 2006; 56: 27-34
- Fetz K, Vogt H, Ostermann T et al. Evaluation of the palliative symptom burden score (PSBS) in a specialised palliative care unit of a university medical centre – a longitudinal study. *BMC Palliative Care* 2018; 1-13. [Copy of paper available on course website].
- Homsí J, Walsh D, Rivera N et al. Symptom evaluation in palliative medicine: patient report vs systematic assessment. *Supportive Care in Cancer* 2006; 14: 444-453.
- Horton R. Differences in assessment of symptoms and quality of life between patients with advanced cancer and their specialist palliative care nurses in a home care setting. *Palliative Medicine* 2002; 16: 488-494
- Hui D, Bruera E. The Edmonton symptom assessment system 25 years later: Past, present and future developments. *Journal of Pain and Symptom Management* 2017; 53: 630-643.
- Kirkova J, Davis M, Walsh D et al. Cancer symptom assessment instruments: A systematic review. *Journal of Clinical Oncology* 2006; 24: 1459-1473.
- Kwok Oi-Ling D, Kam-Hung D. Symptom distress as rated by advanced cancer patients, caregivers and physicians in the last week of life. *Palliative Medicine* 2005; 19: 228-233
- Lam W, Law C, Fu Y et al. New insights in symptom assessments: The chinese versions of the memorial symptom assessment scale short form (MSAS-SF) and the condensed MSAS (CMSAS). *Journal of pain and Symptom Management* 2008; 36: 584-595.
- Lobchuk M. The memorial symptom assessment scale: Modified for use in understanding family caregivers' perceptions of cancer patients' symptom experiences. *Journal of Pain and Symptom Management* 2003; 26: 644-654.

- McPherson C, Wilson K, Lobchuk M et al. Family caregivers' assessment of symptoms in patients with advanced cancer: Concordance with patients and factors affecting accuracy. *Journal of Pain and Symptom Management* 2008; 35: 70-82.
- Mercadante S, Adile C, Lanzetta G et al. Personalised symptom goals and patient global impression on clinical changes in advanced cancer patients. *The Oncologist* 2018; 23: 1-8
- Narducci F, Grande R, Mentuccia L et al. Symptom improvement as a prognostic factor for survival in cancer patients undergoing palliative care: a pilot study. *Supportive Care in Cancer* 2012; 20: 1221-1226
- Nekolaichuk C, Bruera E, Spachynski K et al. A comparison of patient and proxy symptom assessments in advanced cancer patients. *Palliative Medicine* 1999; 13: 311-323
- Nekolaichuk C, Maguire T, Suarez-Almazar M et al. Assessing the reliability of patient, nurse and family caregiver symptom ratings in hospitalised advanced cancer patients. *Journal of Clinical Oncology*; 17: 3621-3630
- Oldenmenger W, de Raaf P, Klerk C et al. Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: A systematic review. *Journal of Pain and Symptom Management* 2013; 45: 1083-1093
- Portenoy R, Thaler H, Kornblith A et al. The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. *European Journal of Cancer* 1994; 30: 1326-1336
- Reilly C, Bruner d, Mitchell S et al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. *Supportive Care in Cancer* 2013; 21: 1525-1550
- Rhondali W, Hui D, Kim S et al. Association between patient reported symptoms and nurses clinical impressions in cancer patients admitted to an acute palliative care unit. *Journal of Palliative Medicine* 2012; 15: 301-307
- Richardson L, Jones G. A review of the reliability and validity of the Edmonton symptom assessment system. *Current Oncology* 2009; 16: 53-64
- Ripamonti C, Bandieri E, Pessi M et al. The Edmonton symptom assessment system (ESAS) as a screening tool for depression and anxiety in non-advanced patients with solid or haematological malignancies on cure or follow-up. *Supportive Care in Cancer* 2014; 22: 783-793

- Seow B, Sussman J, Martelli-Reid L et al. Do high symptom scores trigger clinical actions? An audit after implementing electronic symptom screening. *Journal of Oncology Practice* 2012; 8: 142-148 [Copy of paper available on course website].
- Schulman-Green D, Cherlin E, McCorkle R et al. Benefits and challenges in use of a standard symptom assessment instrument in hospice. *Journal of Palliative Medicine* 2010; 13: 155-159
- Sharp J, Gough K, Pascoe M et al. The modified memorial symptom assessment scale short form: a modified response format and rational scoring rules. *Quality of Life Research* 2018;
- Sikorskii A, Wyatt G, Tamkus D et al. Concordance between patient reports of cancer related symptoms and medical records documentation. *Journal of Pain and Symptom Management* 2012; 44: 362-372
- Spaner D, Caraiscos V, Muystra C et al. Use of standardised assessment tools to improve the effectiveness of palliative care rounds: A quality improvement initiative. *Journal of Palliative Care* 2017; 32: 134-140
- Stewart-Knight K, Parry R, Abey A et al. Does the distress thermometer work? A systematic review of the evidence for its use and validity. *BMJ Supportive and Palliative Care* 2012; 2(supp 1): A1-A120
- Strasser F, Blum D, von Moos R et al. The effect of real time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicentre cluster-randomised phase III study (SAKK 95/06). *Annals of Oncology* 2016; 27: 324-332
- Stromgren A, Sjogren P, Goldschmidt D et al. Symptom priority and course of symptomatology in specialised palliative care. *Journal of Pain and Symptom Management* 2006; 31: 199-206
- Teunissen S, Wesker W, Kruitwagen C et al. Symptom prevalence in patients with incurable cancer: A systematic review. *Journal of Pain and Symptom Management* 2007; 34: 94-104
- Tranmer J, Heyland D, Dudgeon D et al. measuring the symptom experience of seriously ill cancer and noncancer hospitalised patients near the end of life with the memorial symptom assessment scale. *Journal of Pain and Symptom Management* 2003; 25: 420-429

- White C, McMullan D, Doyle J. “Now that you mention it, doctor...” Symptom reporting and the need for systematic questioning in a specialised palliative care unit. *Journal of Palliative Medicine* 2009; 12: 447-450

ORAL PROBLEMS

Andrew Davies

- Davies A, Finlay I. *Oral Care in Advanced Disease*. Oxford: Oxford University Press; 2005.
- Davies AN, Epstein JB. *Oral Complications of Cancer and its Management*. Oxford: Oxford University Press; 2010.
- Davies AN. Oral care. In: Cherny N, Fallon M, Kaasa S, Portenoy R, Currow D, editors. *Oxford textbook of Palliative Medicine*, 5th edition. Oxford: Oxford University Press; 2015.

OLD VS NEW: HALOPERIDOL VS OLANZAPINE

Andrew Dickman

- Prommer E. Olanzapine: palliative medicine update. *Am J Hosp Palliat Care*. 2013;30(1):75-82.
- Digges M, Hussein A, Wilcock A, Crawford GB, Boland JW, Agar MR, et al. Pharmacovigilance in Hospice/Palliative Care: Net Effect of Haloperidol for Nausea or Vomiting. *J Palliat Med*. 2018;21(1):37-43.
- Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. 2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer. *Support Care Cancer*. 2017;25(1):333-40.
- Van Der Vorst M, Neefjes ECW, Boddaert MSA, Verdegaal BATT, Beeker A et al. Efficacy and side effect profile of olanzapine versus haloperidol for symptoms of delirium in hospitalized patients with advanced cancer: A multicenter, investigator-blinded, randomized, controlled trial (RCT). *J Clin Oncol* 2017;35(31 suppl):231-231.
- Hui D, Dev R, Bruera E. Neuroleptics in the management of delirium in patients with advanced cancer. *Curr Opin Support Palliat Care*. 2016;10(4):316-323. [Copy of paper available on course website].
- Meyer JM, Simpson GM. From chlorpromazine to olanzapine: a brief history of antipsychotics. *Psychiatr Serv*. 1997;48(9):1137-9. [Copy of paper available on course website].

- Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, et al. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. *Psychosomatics*. 2018;59(2):105-22.

CORTICOSTEROIDS - BENEFITS AND RISKS

Kath Webber

- Stina Dinsen, Bo Baslund, Marianne Klose, Aase Krogh Rasmussen, Lennart Friis-Hansen, Linda Hilsted, and Ulla Feldt-Rasmussen. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. *European Journal of Internal Medicine*, 2013 vol. 24 (8) pp. 714-720.
- Alison Haywood, Phillip Good, Sohil Khan, Aurelia Leupp, Sue Jenkins-Marsh, Kirsty Rickett, and Janet R Hardy. Corticosteroids for the management of cancer-related pain in adults. *Cochrane Database of Systematic Reviews*, 2015 vol. 41 (4) p. 459.
- David Hui, Kelly Kilgore, Susan Frisbee-Hume, Minjeong Park, Anne Tsao, Marvin Delgado-Guay, Charles Lu, William William Jr., Katherine Pisters, George Eapen, Frank Fossella, Sapna Amin, and Eduardo Bruera. Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. *J Pain Symptom Manage*, 2016 vol. 52 (1) pp. 8-16.e1.
- Jessica L Hwang and Roy E Weiss. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. *Diabetes Metab Res Rev*, 2014 vol. 30 (2) pp. 96-102.
- Leon Margolin, Doris K Cope, Rachel Bakst-Sisser, and Joshua Greenspan. The Steroid Withdrawal Syndrome: A Review of the Implications, Etiology, and Treatments. *J Pain Symptom Manage*, 2007 vol. 33 (2) pp. 224-228.
- Ollie Minton, Alison Richardson, Michael Sharpe, Matthew Hotopf, and Patrick Stone. Drug therapy for the management of cancer-related fatigue. *Cochrane Database of Systematic Reviews*, 2010 vol. 1 (3) p. 140.
- Ørnulf Paulsen, Pål Klepstad, Jan Henrik Rosland, Nina Aass, Eva Albert, Peter Fayers, and Stein Kaasa. Efficacy of Methylprednisolone on Pain, Fatigue, and Appetite Loss in Patients With Advanced Cancer Using Opioids: A Randomized, Placebo-Controlled, Double-Blind Trial. *Journal of Clinical Oncology*, 2014 vol. 32 (29) pp. 3221-3228.
- D Tomlinson, P D Robinson, S Oberoi, D Cataudella, N Culos-Reed, H Davis, N Duong, F Gibson, M Götte, P Hinds, S L Nijhof, P Van der Torre, S Cabral, L L

Dupuis, and L Sung. Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis. *Curr Oncol*, 2018 vol. 25 (2) p. 152.

- Petra Vayne-Bossert, Alison Haywood, Phillip Good, Sohil Khan, Kirsty Rickett, and Janet R Hardy. Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). *Cochrane Database of Systematic Reviews*, 2017 vol. 28 (4) p. 381.

UPDATE ON BISPHOSPHONATES / DENOSUMAB

Sarah Cox

- Dietzek A, Connelly K, Cotugno M, et al. (2015) Denosumab in hypercalcemia of malignancy: a case series. *J Oncol Pharm Pract*; 21:143-7.
- Karuppiah D, Thanabalasingham G, Shine B, et al. (2014) Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab. *Eur J Endocrinol*; 171:K1-5.
- Adhikaree J, Newby Y, Sundar S. (2014) Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy. *BMJ Case Rep*; 2014.
- Hu MI, Glezerman IG, Leboulleux S, et al. (2014) Denosumab for treatment of hypercalcemia of malignancy. *J Clin Endocrinol Metab*; 99:3144-52.
- Coleman R, Body JJ, Aapro M, et al. (2014) Bone health in cancer patients: ESMO Clinical Practice Guidelines. *Ann Oncol*; 25 Suppl 3:iii124-37.
- National Institute for Health and Care Excellence (2014) Prostate cancer; diagnosis and management (NICE Guideline 175).
Available at: <https://www.nice.org.uk/guidance/cg175>
- National Institute for Health and Care Excellence (2012) Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (NICE guidance TA265)
Available at: <https://www.nice.org.uk/guidance/ta265>
- Fizazi K, Carducci M, Smith M, et al. (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet*; 377:813-22.
- O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N Goodwin A. (2017) Bisphosphonates and other bone agents for breast cancer. *Cochrane Database Syst Rev* Oct 30;10:CD003474. doi: 10.1002/14651858.CD003474.pub4.

- Stopeck AT, Lipton A, Body JJ, et al. (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol*; 28:5132-9.
- Barrett-Lee P, Casbard A, Abraham J et al. (2014) Oral Ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. *Lancet Oncol*; 15:114-22.
- Van Poznak C, Somerfield MR, Barlow WE, et al. (2017) Role of bone-modifying agents in metastatic breast cancer: An American Society of Clinical Oncology–Cancer Care Ontario focused guideline update. *J Clin Oncol*; 35:3978-86.
- Shapiro CL, Moriaty JP, Dusetzina S et al (2017) Cost- effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604. *J Clin Oncol*; 35:3949-55.
- Himelstein AL, Foster JC, Khatcheressian JL, et al. (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. *JAMA*; 317:48-58.
- Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. (2017) Bisphosphonates in multiple myeloma: an updated network meta-analysis. *Cochrane Database Syst. Rev* Dec 18;12:CD003188. doi: 10.1002/14651858.CD003188.pub4.
- P Hadji, R E. Coleman, C Wilson et al. (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. *Ann Oncol*; 27:379-90.
- NICE evidence summary (ES15) Published date July 2017. Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates
- Early Breast Cancer Trialists' Collaborative Group (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet*; 386:1353-61.
- Dhesy-Thind S, Fletcher GG, Blanchette PS et al (2017) Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*; 35:2062-81
- MHRA/CHM advice: Denosumab: minimising the risk of osteonecrosis of the jaw; monitoring for hypocalcaemia—updated recommendations (September 2014) and Denosumab: osteonecrosis of the jaw—further measures to minimise risk (July 2015)

- MHRA/CHM advice: Denosumab: reports of osteonecrosis of the external auditory canal (June 2017)
- MHRA/CHM advice: Denosumab (Xgeva®) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation (June 2018)
- MHRA/CHM advice: Denosumab (Xgeva®) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronic acid (zoledronate) (June 2018)

VENOUS THROMBOEMBOLISM

Simon Noble

- Carrier M, Khorana AA, Zwicker JI, Noble S, Lee AYY Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. *Journal Thrombosis and Haemostasis* 2013 September; 11(9) 1760-65
- Lloyd AJ, Dewilde S, Noble S, Reimer E, Lee AYY. What impact does venous thromboembolism and bleeding have on cancer patients' quality of life? *Value Health*. 2018 Apr;21(4):449-455. doi: 10.1016
- Font C, Garcia-Fernandez T, Nelson A, Prout H, Noble S. Patients' Experiences of Living with CANcer associated thrOmbosis in Spain (PELICANOS). *Supportive Care in Cancer* 2018. Apr 7. doi: 10.1007/s00520-018-4174-5.
- Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M. "Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH" *Journal Thrombosis and Haemostasis*. 2018 Apr 2. doi: 10.1111/jth.14015
- Noble S. Are new anticoagulants a safe and reasonable alternative to low molecular heparins? *Thromb Res*. 2018 Apr;164 Suppl 1:S157-S161.
- Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O'Connell C, Carrier M. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. *J Thromb Haemost*. 2018 Jun 29. doi: 10.1111/jth.14219
- G.E. Raskob, N. van Es, P. Verhamme, M. Carrier, M. Di Nisio, D. Garcia, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism, *N. Engl. J. Med.* (2017),

- Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). *J Clin Oncol*. 2018 Jul 10;36(20):2017-2023.

WHAT ELSE IS NEW (SYMPTOMS)

Andrew Davies

- Simon ST, Weingartner V, Higginson IJ et al. Definition, categorization, and terminology of episodic breathlessness: consensus of an international Delphi survey. *Journal of Pain and Symptom Management* 2014; 47: 828-38.
- Simon ST, Weingartner V, Higginson et al. "I can breathe again!" Patients' self-management strategies for episodic breathlessness in advanced disease, derived from qualitative interviews. *Journal of Pain and Symptom Management* 2016; 52: 228-34.
- Jatoi A, Qin R, Satele D et al. "Enjoy a glass of wine before eating": a randomized trial to test the orexigenic effects of this advice in advanced cancer patients. *Supportive Care in Cancer* 2016; 24: 3739-46.
- Kerr D. Alcohol and palliative care. *Palliative Medicine* 1992; 6: 185-201.
- Twycross RG, Gilhooley RA. Euphoriant elixir. *British Medical Journal* 1973 4: 552.

TERMINAL SEDATION - THE RIGHTS AND WRONGS!

Craig Gannon

- Lomas C, 'Dying patients denied pain relief because of legal fears', *Nursing Times*, 18 May, 2010
- Willis D, Gannon C, Harlow T, Idris Baker I, & George R 'A response to L. Anquinet et al.'s article on terminal sedation' *Palliative Medicine*, 2014; pp. 367-368
- Raus K; Sterckx S, 'How defining clinical practices may influence their evaluation: the case of continuous sedation at the end of life' *Journal of Evaluation in Clinical Practice*, 2016; 22(3):425-32
- Royal College of Physicians 'Prolonged disorders of consciousness: National clinical guidelines' London, RCP, 2013
- Glannon W. 'The Value and Disvalue of Consciousness' *Cambridge Quarterly of Healthcare Ethics*, 2016; 25(4):600-12

- Cohen-Almagor & Ely, 'Euthanasia and palliative sedation in Belgium', *BMJ Support Palliative Care*, 2018; 8(3): 307-313
- Bruinsma SM; van der Heide A; van der Lee ML; Vergouwe Y; Rietjens JA. 'No Negative Impact of Palliative Sedation on Relatives' Experience of the Dying Phase and Their Wellbeing after the Patient's Death: An Observational Study' *PLoS ONE*, 2016; 11(2):e0149250
- Beller EM, van Driel M, McGregor L, Truong S, Mitchell G. Palliative pharmacological sedation for terminally ill adults. *Cochrane Database of Systematic Reviews* 2015, Issue 1. Art. No.: CD010206. DOI: 10.1002/14651858.CD010206.pub2
- Agar MR, Lawlor PG, Quinn, S, Draper B, Caplan GA; Rowett D, Sanderson C, Hardy J, Le B, Eckermann S, McCaffrey N, Devilee L, Fazekas B, Hill M, & Currow DC, 'Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care A Randomized Clinical Trial' *JAMA Intern Med*, 2017; 177(1): 34-42
- van Deijck RH; Hasselaar JG; Verhagen SC; Vissers KC; Koopmans RT 'Patient-Related Determinants of the Administration of Continuous Palliative Sedation in Hospices and Palliative Care Units: A Prospective, Multicenter, Observational Study' *Journal of Pain & Symptom Management*, 2016; 51(5):882-9
- Twycross R, 'Second thoughts about palliative sedation' *Evidence Based Nursing*, 2017; 20(2):33-34
- Davies J, Willis D & George R 'The double effect is no doctrine: it's a reflective tool part I' *EJPC*, 2017; 24 (4): 178-182
- Wheeler R, 'Doctrine of Double Effect', *Bulletin of the Royal College of Surgeons of England*, 2016; 98(5):220-220